BACKGROUND/AIM: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. PATIENTS AND METHODS: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. RESULTS: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. CONCLUSION: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR-/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.

Department of Clinical and Radiation Oncology Pardubice Hospital Pardubice Czech Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Oncology and Radiotherapy Faculty of Medicine in Hradec Kralove Charles University Hradec Kralove Czech Republic

Department of Oncology and Radiotherapy University Hospital Hradec Kralove Hradec Kralove Czech Republic

Department of Oncology General University Hospital Prague Prague Czech Republic

Department of Oncology Palacky University Medical School and Teaching Hospital Olomouc Czech Republic

Department of Radiotherapy and Oncology 3rd Faculty of Medicine Charles University Prague Czech Republic

Faculty of Health Studies Pardubice University Pardubice Czech Republic

Institute for Postgraduate Medical Education Prague Czech Republic

Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

Oncology Centre Multiscan Pardubice Czech Republic

The Fingerland Department of Pathology Charles University Medical Faculty and University Hospital Hradec Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247. doi: 10.1146/annurev-med-070909-182917. PubMed DOI PMC

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich, McGuire WL. Human breast cancer: correlation of relapse and survival with amplificationof the HER-2/neu oncogene. Science. 1987;235(4785):177–182. doi: 10.1126/science.3798106. PubMed DOI

Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care. 2013;8(4):256–262. doi: 10.1159/000354253. PubMed DOI PMC

Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009;27(34):5838–5847. doi: 10.1200/JCO.2009.22.1507. PubMed DOI

Moasser MM. The oncogene HER2; its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469–6487. doi: 10.1038/sj.onc.1210477. PubMed DOI PMC

Wu VS, Kanaya N, Lo C, Mortimer J, Chen S. From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer. J Steroid Biochem Mol Biol. 2015;153:45–53. doi: 10.1016/j.jsbmb.2015.05.005. PubMed DOI PMC

Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol. 2008;5(9):531–542. doi: 10.1038/ncponc1179. PubMed DOI

Lousberg L, Collignon J, Jerusalem G. Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol. 2016;8(6):429–449. doi: 10.1177/1758834016665077. PubMed DOI PMC

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi: 10.1093/jnci/dju055. PubMed DOI PMC

Kolarova I, Vanasek J, Dolezal M, Stuk J, Hlavka A, Dusek L., Melichar B, Büchle T, Ryška A, Prausová J, Petrakova K, Tesarova P, Petera J, Vosmik M, Horacova K, Jarkovsky J. Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2- positive breast cancer patients: analysis of real-world clinical practice based on a research database. Neoplasma. 2020 doi: 10.4149/neo_2020_191023N1080. PubMed DOI

Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619–626. doi: 10.1158/1055-9965.EPI-17-0627. PubMed DOI

Chumsri S, Li Z, Serie DJ, Mashadi-Hossein A, Colon-Otero G, Song N, Pogue-Geile K, Gavin P, Paik S, Moreno-Aspitia A, Perez EA, Thompson EA. Incidence of late relapse in HER2-positive (HER2+) breast cancer patients receiving adjuvant trastuzumab: Combined analysis of NCCTG (Alliance) N9831 and NSABP (NRG) B31 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Cancer Res. 2019;79(4Suppl):Abstract PD3-02. doi: 10.1158/1538-7445.SABCS18-PD3-02. PubMed DOI PMC

Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF, Czene K. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol. 2011;29(30):4014–4021. doi: 10.1200/JCO.2010.32.6462. PubMed DOI

Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34(9):927–935. doi: 10.1200/JCO.2015.62.3504. PubMed DOI PMC

Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D’Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F. “Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome. Oncotarget. 2016;7(14):17932–17944. doi: 10.18632/oncotarget.7480. PubMed DOI PMC

Montemurro F, Rossi V, Cossu Rocca M, Martinello R, Verri E, Redana S, Adamoli L, Valabrega G, Sapino A, Aglietta M, Viale G, Goldhirsch A, Nolè F. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer. 2012;118(1):17–26. doi: 10.1002/cncr.26162. PubMed DOI

Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP, American Society of Clinical Oncology Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(19):2078–2099. doi: 10.1200/JCO.2013.54.0948. PubMed DOI PMC

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) Ann Oncol. 2017;28(1):16–33. doi: 10.1093/annonc/mdw544. PubMed DOI PMC

Larionov AA. Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients. Front Oncol. 2018;8:89. doi: 10.3389/fonc.2018.00089. PubMed DOI PMC

Zhao S, Liu XY, Jin X, Ma D, Xiao Y, Shao ZM, Jiang YZ. Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer. Theranostics. 2019;9(17):4935–4945. doi: 10.7150/thno.35730. PubMed DOI PMC

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, CLEOPATRA Study Group Pertuzumab, trastuzumab and docetaxel in HER2-pozitive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. doi: 10.1056/NEJMoa1413513. PubMed DOI PMC